slidedeck.co

Moderna, Inc. investor presentation, Third Quarter 2026 earnings call

Cover slide of the Moderna, Inc. 2026 investor presentation
Cover of Moderna, Inc.'s 2026 investor presentation.

The deck opens with a title slide and a forward-looking statements disclaimer, then an agenda naming the four speakers. The Business Review section gives a financial summary, business highlights across commercial milestones, oncology pipeline and corporate updates, and a welcome slide for a new Chief Operating Officer. The Financials section covers revenue through 3Q26 on a bar chart, a detailed GAAP results table, and an updated 2026 financial framework laid out as a table of line items with change-from-previous notes. The Business updates section sets out a multi-year revenue growth strategy as a rising timeline with product bands, followed by approved-product and U.S. respiratory vaccination market slides. The Pipeline updates section covers infectious disease and oncology programmes, with Phase 3 intismeran results shown across several slides, and rare disease programmes. The Looking Ahead section lists 2026 value drivers, upcoming events and a Q&A slide, and the appendix holds full pipeline charts by therapeutic area. Slides are dense with footnotes and tables, and most follow a headline-style title with a section tag down the left edge.

Slides worth studying

  • Slide 3: The agenda uses a clear list of speakers with icons and a highlighted active item that repeats in each section divider, giving the audience a consistent sense of place.
  • Slide 8: A stacked bar chart of revenue by quarter with one short takeaway column beside it makes the key number readable at a glance.
  • Slide 14: Large figures for each vaccine category are paired with a small year-over-year comparison, so the market message is carried by the numbers themselves.
  • Slide 12: A rising timeline graphic with product bands across 2026 to 2028 turns the multi-year strategy into a single visual sequence.

Details

  • Company: Moderna, Inc.
  • Year: 2026
  • Type: Investor presentation
  • Industry: Biotechnology
  • Pages: 32

The hosted copy of this deck is being prepared. Newsletter readers will find the download here.

Review score: 7 out of 10, Effective

Presentation quality, judged with the SlideDeck Co review heuristic. Ask, evidence and idea merit are not rated here.

The deck has a clear, repeatable structure: a left-edge section tag, headline-style titles in consistent red, a recurring agenda slide that highlights the current section (3, 7, 11, 16, 24), and a consistent logo. The detailed slides are well made: slide 8 has a clean stacked chart with a takeaway title and three short bullets, and slide 14 has a clear paired-bar chart with a highlighted +3% total. Weaknesses are consequential. Many slides carry tiny type that cannot be read at presentation size, including the disclaimer on slide 2, the results table on slide 9, the survival curves and AE chart on slides 18 to 21, and the appendix on slides 30 to 32. Several pages are sparse or poorly filled, such as slide 23 with two near-empty cards, slide 15 and slide 32, and the agenda is repeated five times. Slide 8 also reads oddly because the 3Q26 bar floats in a waterfall-like layout with no visible connection to the YTD bar.

Worth keeping: Keep the section-tag system, the highlighted agenda dividers, and the takeaway headlines with chart plus short commentary as on slides 8 and 14.

Most useful repair: Enlarge or crop the unreadable tables and charts on slides 9, 19 to 21 and 30 to 32, and fill or merge the near-empty slides such as 23 and 32.

What would change the score: I would cut the repeated agenda slides to one or fold them into the section tags, and give the key framework and growth strategy slides (10, 12) fewer, larger elements.

Confidence medium. 32 of 32 pages inspected on contact sheets, 4 at readable size. Reviewed 2026-11-10. Model-assisted review (claude-sonnet-5-5).

Full text of the slides (32 slides)

Every slide's words and a description of its charts and images, so the deck can be searched and rebuilt. Also available as Markdown.

Slide 1

Third Quarter 2026

Financial Results

November 6, 2026

© 2026 Moderna, Inc. All rights reserved.

moderna

Visuals: Three line icons in identical blue-outlined circles, read left to right: (1) a red open hand holding a blue medical cross, (2) a set of arrows, with a blue diagonal arrow pointing up-right in the centre, a red arrow pointing up-right on the upper left, and a red arrow turning upward on the lower right, (3) a red sine-like wave curve with three short blue vertical tick marks beneath its trough and blue vertical marks at its ends. Each icon is a 200 by 200 pixel image, about 7.5% wide and 13.3% tall, with a blue circle stroke of about 2 px and no fill. Also present is the Moderna wordmark in red lowercase letters with a dashed underline that fades from light blue on the left to deeper cyan on the right. The wordmark is a logo image, not a photograph, and it is not cropped.

Slide 2

Forward-looking statements and disclaimer

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements

regarding: Moderna's updated 2026 financial framework, including 15-25% revenue growth and further cost reductions in 2026; Moderna's expected year-end cash

balance; Moderna’s multi-year revenue growth strategy; Moderna's 2026 value drivers; planned 2028 market expansion for mNEXSPIKE; Moderna's ability to deliver

cost efficiency across the business; the potential of intismeran and Moderna's broader oncology portfolio; Moderna's multi-year strategic partnerships; Moderna’s

regulatory filings under review and potential approvals, including timing of approvals; anticipated regulatory filings; momentum in the U.S. respiratory vaccination

market and future demand; next steps for the mRNA-1403 program; the RFS benefit of intismeran plus pembrolizumab emerging over time; the use of proceeds from

Moderna’s convertible notes financing, including to support oncology growth and debt repayment; and anticipated progress and milestones for Moderna's pipeline

programs, including potential near-term data readouts and other catalysts. In some cases, forward-looking statements can be identified by terminology such as “will,”

“may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other

comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises

nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and

other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these

forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk

Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in

subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any

intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future

developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this presentation.

Financial figures in this presentation as of, and for the quarterly periods ended, September 30, 2026, and September 30, 2025, are unaudited.

2

© 2026 Moderna, Inc. All rights reserved.

moderna

Visuals: Moderna logo (wordmark in red with a row of short cyan dashes beneath it) at the bottom right corner. No charts, photographs or other illustrations.

Slide 3

3Q26 earnings call agenda / Business Review / Stéphane Bancel, CEO / Financials / Jamey Mock, CFO / Business updates / Stephen Hoge, M.D., President / Pipeline updates / David Berman, M.D., Ph.D., Chief Development Officer / Looking Ahead / Stéphane Bancel, CEO / © 2026 Moderna, Inc. All rights reserved.

Visuals: Five circular line icons in a column, each a thin outlined circle about 4.8% wide containing a small pictogram. Row 1 icon: red (#E21D39) circle outline with a red sine-wave curve and small blue (#2AACE2) tick marks, representing a business trend review. Row 2 icon: grey (#C0C0C0) circle with a grey outlined dashboard window containing a bar chart and a pie chart. Row 3 icon: grey circle with three grey outlined test tubes or pipettes at diagonal angles. Row 4 icon: grey circle with a grey outlined microscope beside a cluster of grey outlined hexagons. Row 5 icon: grey circle with two rows of grey outlined rounded rectangles followed by arrow shapes pointing right. Also the Moderna wordmark logo in red (#E31837) lowercase letters with a row of light blue (#2AACE2) dashes beneath, bottom right.

Slide 4

3Q26 financial summary

Revenue

$1.3B

Net income

$0.2B

Cash & investments

$8.0B

Continuing to execute with financial discipline

Reduced cash costs¹ by 10% in 3Q26 compared to 3Q25

1.Cash costs = GAAP expenses − stock-based compensation − depreciation and amortization

© 2026 Moderna, Inc. All rights reserved.

4

Business Review

3Q 2026 Update |

moderna

Visuals: Three stat blocks with no chart: 1) label 'Revenue' above value '$1.3B'; 2) label 'Net income' above value '$0.2B'; 3) label 'Cash & investments' above value '$8.0B'. Values are large bold numerals in blue. Two thin vertical light grey rules (about 0.1% wide, about 30.6% of height, colour #BFBFBF) run between the stat columns at about x 22.3% and x 50.0%, spanning about y 21.8% to 52.4%. One rounded rectangle callout (fill #BFE6F6, no border, small corner radius) contains a bold headline and a regular sentence with superscript 1 after 'costs'. One image: the Moderna logo (359 by 81 pixels) at bottom right, consisting of the lowercase red wordmark 'moderna' in red #E31837 with a registered mark, above a row of short dashed cyan-blue line segments (about #2AACE2 to #00B0E0) spanning the logo width. No photographs, icons or charts.

Slide 5

Business highlights in 3Q

Commercial milestones

Oncology pipeline

Corporate updates

Approved by U.S. FDA

and Health Canada

mFLUSIVA® Influenza Vaccine, mRNA

Approved by Health Canada

mCOFLU® Combined Influenza and COVID-19 mRNA Vaccine

Flu + COVID-19 combination vaccine

(mRNA-1083) under brand name mCOFLU®

Intismeran autogene mRNA-4157

• Presented Phase 3 data at the ESMO¹ 2026 Presidential Symposium, demonstrating a 42% reduction in the risk of recurrence or death with intismeran + KEYTRUDA® vs. KEYTRUDA alone in resected melanoma

• A prespecified sensitivity analysis in the modified intent-to-treat² population demonstrated a 49% reduction in the risk of recurrence or death with intismeran + KEYTRUDA vs KEYTRUDA alone in resected melanoma

Link to presentation

Financing

Raised $3.0B through 0% convertible notes³ due 2032, providing flexibility to support oncology growth and debt repayment

CEPI collaboration

mRNA-1469, an investigational Ebola vaccine in collaboration with CEPI, has been selected to advance into a Phase 2/3 study, following WHO Technical Advisory Group recommendation

1. ESMO: European Society for Medical Oncology

2. The modified intent-to-treat (mITT) population excludes participants who did not receive at least one dose of intismeran or placebo as planned

3. Net issuance proceeds of $2.6B after purchase of capped calls and incurred fees; ***subject to regulatory approval.

© 2026 Moderna, Inc. All rights reserved.

3Q 2026 Update | Business Review

5

moderna

Visuals: Three logos and one icon. (1) mFLUSIVA logo, a red-crimson wave-in-rounded-square mark with the word mFLUSIVA® in crimson and the line Influenza Vaccine, mRNA in grey beneath, placed in a box at x 7.0 y 31.2 w 21.8 h 21.5 (581 by 322 px). (2) mCOFLU logo, a coral-red wave-in-rounded-square mark with the word mCOFLU® in coral and the lines Combined Influenza and / COVID-19 mRNA Vaccine in grey, placed at x 8.9 y 58.4 w 18.4 h 17.4 (489 by 260 px). (3) Moderna wordmark in red #E31837 with a row of dashed cyan-blue underline dashes beneath, bottom-right at x 86.6 y 92.2 w 12.2 h 4.9 (359 by 81 px). (4) Red document icon with folded top-right corner and three white horizontal lines, about x 39.5 y 77.5 w 2.5 h 3.0, beside the link text. No photographs or charts. The mFLUSIVA and mCOFLU logos sit on white with no boxes or overlays.

Slide 6

Moderna welcomes Juan Andres as Chief Operating Officer

Business Review

3Q 2026 Update |

•

As Chief Operating Officer, Juan leads

Moderna’s operational strategy and execution,

including oversight of the Company’s global

manufacturing organization

•

Returns to Moderna after six years leading the

build-out and rapid scale-up of Moderna’s

global manufacturing network

to support COVID-19 vaccine production

and intismeran autogene manufacturing

6

© 2026 Moderna, Inc. All rights reserved.

Visuals: Photograph: a smiling middle-aged man with short greying dark hair, seen from the chest up, turned slightly to his left (viewer's left) with his head tilted, mouth open in a laugh. He wears a brown wool jacket with a blue-grey windowpane check and an open-collared white shirt. The background is a pale light-blue plain wall, softly lit. Lighting is soft and even from the front, with no hard shadows. Composition is a portrait crop: head and shoulders fill the frame, cropped at the bottom edge of the jacket and at the sides of the photo. The photo is a rectangle with very slightly rounded corners, not full-bleed, boxed within a light grey (#EDEDED) backing rectangle, with no overlay or tint. Logo: the Moderna wordmark in lowercase red letters (#E31837) with a row of short cyan (#2AACE2) dashes beneath it, bottom-right. No charts, tables or diagrams.

Slide 7

3Q26 earnings call agenda

Business Review

Stéphane Bancel, CEO

Financials

Jamey Mock, CFO

Business updates

Stephen Hoge, M.D., President

Pipeline updates

David Berman, M.D., Ph.D., Chief Development Officer

Looking Ahead

Stéphane Bancel, CEO

© 2026 Moderna, Inc. All rights reserved.

Visuals: Six line icons in a column at x 23.2%, each about 4.8% wide by 8.6% high, inside outlined circles. 1) Business Review (y 16.7%): grey circle outline with a grey wave or curve glyph with tick marks. 2) Financials (y 32.4%): red #E21D39 circle outline containing a blue and red presentation board with a bar chart (two red bars, two blue bars) and a blue pie chart. 3) Business updates (y 48.4%): grey circle outline with three diagonal grey test tubes in a rack. 4) Pipeline updates (y 63.8%): grey circle outline with a grey microscope beside grey hexagon molecule shapes. 5) Looking Ahead (y 79.5%): grey circle outline with two rows of grey rounded rectangles each ending in a grey arrow. One rounded red outline rectangle surrounds the Financials row, spanning about x 21.0% to 78.5% and y 30.0% to 44.0%. One Moderna logo: red #E21D39 lowercase wordmark 'moderna' with a dashed cyan underline, about 12.2% wide, bottom right.

Slide 8

3Q26 revenue of $1.3B, 1Q-3Q total of $1.8B

Revenue through 3Q26

$1.3B

$1.8B

$0.5B

International

U.S.

0.5

0.8

0.4

0.9

0.9

0.2

1H26

3Q26

YTD

Strength in 3Q driven by increased

demand, operational execution, and

timing of shipments between 3Q and 4Q

Increased 2026 revenue outlook to

15-25% growth, exceeding prior

expectation of up to 10% growth

Continue to expect approximately even

split between U.S. and International

revenue for 2026

Values rounded to nearest $0.1B; totals may differ due to rounding

8

© 2026 Moderna, Inc. All rights reserved.

Financial Review

3Q 2026 Update |

Visuals: One chart, a stacked column chart reproduced as a picture, titled 'Revenue through 3Q26' (bold black, centred above the chart at y 22.6). Three columns on a shared baseline with no y-axis, no gridlines and no numeric axis labels; category labels beneath the baseline read '1H26', '3Q26' and 'YTD' in large light sans-serif. Series: International (navy #1F2A44 segments, labels in white) and U.S. (light blue #2AACE2 segments, labels in white). Values printed in segments: 1H26 International 0.4, U.S. 0.2, total $0.5B; 3Q26 International 0.5, U.S. 0.8, total $1.3B; YTD International 0.9, U.S. 0.9, total $1.8B. Totals are printed above each column in bold red #E31837 (about 3.3% of slide height). Legend at top-left of the chart: a navy square labelled 'International' and a light-blue square labelled 'U.S.'. Thin grey connector lines (#A6A6A6, about 0.1% of slide height) run horizontally from the top of the 1H26 column at the $0.5B level to the 3Q26 column, and from the top of the 3Q26 column at $1.3B to the top of the YTD column. Small grey tick marks sit on the baseline between columns. No value is highlighted beyond the red totals. The moderna logo is a red (#E31837) wordmark with a row of short light-blue (#2AACE2) dashes beneath it, placed bottom-right, unboxed.

Slide 9

3Q 2026 financial results

Financial Review

3Q 2026 Update |

In $ millions, except per share amounts

3Q 2026

3Q 2025

Change

(3Q'26 vs. 3Q'25)

Net product sales / $ 1,273 / $ 973 / $ 300 / 31 % / Other revenue1 / 40 / 43 / (3) / (7) % / Total revenue / 1,313 / 1,016 / 297 / 29 % / Cost of sales / 318 / 207 / 111 / 54 % / Research and development / 583 / 801 / (218) / (27) % / Selling, general and administrative / 282 / 268 / 14 / 5 % / Total operating expenses / 1,183 / 1,276 / (93) / (7)% / Income (loss) from operations / 130 / (260) / 390 / 150 % / Other income, net / 41 / 73 / (32) / (44) % / Provision for income taxes / 9 / 13 / (4) / (31) % / Net income (loss) / $ 162 / $ (200) / $ 362 / 181 % / Earnings (loss) per share – Diluted / $ 0.38 / $ (0.51) / $ 0.89 / 175 % / Weighted average shares – Diluted2 / 430 / 390 / 40 / 10 % / Weighted average shares – Basic2 / 401 / 390 / 11 / 3 % / Effective tax rate / 5 % / (7)%

1Includes grant, collaboration, licensing and royalty, and stand-ready manufacturing revenue

2We generated a net loss in the prior period presented, therefore the basic and diluted calculation was the same in 3Q 2025

In $ billions

9/30/2026

6/30/2026

Change

(9/30 vs. 6/30)

Cash, cash equivalents and investments / $ 8.0 / $ 6.9 / $ 1.1 / 16 %

© 2026 Moderna, Inc. All rights reserved.

9

Visuals: One table, no chart or photograph. Main table columns: row label; 3Q 2026; 3Q 2025; Change (3Q'26 vs. 3Q'25) in dollars; Change in percent. Rows in order: Net product sales $1,273 / $973 / $300 / 31 %; Other revenue1 40 / 43 / (3) / (7) %; Total revenue 1,313 / 1,016 / 297 / 29 %, shaded row; Cost of sales 318 / 207 / 111 / 54 %; Research and development 583 / 801 / (218) / (27) %; Selling, general and administrative 282 / 268 / 14 / 5 %; Total operating expenses 1,183 / 1,276 / (93) / (7)%, shaded row; blank spacer row; Income (loss) from operations 130 / (260) / 390 / 150 %, shaded row; Other income, net 41 / 73 / (32) / (44) %; Provision for income taxes 9 / 13 / (4) / (31) %; Net income (loss) $162 / $(200) / $362 / 181 %, shaded row; Earnings (loss) per share – Diluted $0.38 / $(0.51) / $0.89 / 175 %; Weighted average shares – Diluted2 430 / 390 / 40 / 10 %; Weighted average shares – Basic2 401 / 390 / 11 / 3 %; Effective tax rate 5 % / (7)% with no change entries. Shaded rows (light grey #F2F2F2 bands) are Total revenue, Total operating expenses, Income (loss) from operations and Net income (loss). Second table: header cells 9/30/2026, 6/30/2026 and Change (9/30 vs. 6/30) in dark blue; one data row Cash, cash equivalents and investments $8.0 / $6.9 / $1.1 / 16 %. No chart, legend or highlighted points. Logo: moderna wordmark in red with a row of short cyan dashes beneath it.

Slide 10

Updated 2026 GAAP financial framework / UPDATED FRAMEWORK / CHANGE FROM PREVIOUS / Total revenue / 15-25% growth from 2025 / (Expect 2026 revenue to be approximately even split between U.S. and International) / Increased from up to 10% growth from 2025 / (Expect 2026 revenue split of ~50% U.S. and ~50% International) / Cost of sales1 / ~$1.7B / Unchanged / ~$4.5B / GAAP expenses excluding $0.9B litigation settlement charge / R&D / ~$2.7B / Improved from $2.9B / ~$3.8B / adjusted cash costs2 excluding $0.9B litigation settlement charge / SG&A / ~$1.0B / Unchanged / Tax / Negligible / Unchanged / Capital expenditures / $0.2B / Improved to low end of prior $0.2–0.3B range / Cash and investments / 2026 year-end balance of $8.1-8.3B / (Excludes any further drawdowns from the Company’s remaining $0.9B available under its credit facility) / Increase driven by improved operational execution and net proceeds from convertible debt issuance / 1. Includes $0.9B litigation settlement charge / 2. Excluding $0.9B for litigation settlement charge. Cash costs = GAAP expenses − stock-based compensation − depreciation and amortization / 10 / © 2026 Moderna, Inc. All rights reserved. / 3Q 2026 Update | Financial Review

Visuals: No charts, photographs or icons. Non-text elements: (1) a solid light-blue (#2AACE2) vertical sidebar along the left edge, 2.7% wide, full height. (2) Seven light-blue (#BFE6F6) rectangular label boxes behind the row labels Total revenue, Cost of sales, R&D, SG&A, Tax, Capital expenditures and Cash and investments, square corners, no outline. (3) Thin grey horizontal rules (about #BFBFBF, 1 px) between rows at about y 26%, 37.7%, 46.2%, 54.7%, 63.2% and 74.8%, spanning x 5.4% to 86%. (4) A dashed grey vertical divider (about #A6A6A6) at x 56.4% from y 13.8% to 86%. (5) A light-blue (#2AACE2) bracket line, about 1.5 px, from the top of the cost values (x 24.8%, y 31%) down to y 52.6% at x 27.8%, with a short horizontal tick from it to x 30% at y 41.7%, grouping Cost of sales, R&D and SG&A. (6) Moderna logo bottom-right: the red (#E31837) lowercase wordmark 'moderna' with a row of short dashed light-blue (#2AACE2) underline dashes beneath it.

Slide 11

3Q26 earnings call agenda

Business Review

Stéphane Bancel, CEO

Financials

Jamey Mock, CFO

Business updates

Stephen Hoge, M.D., President

Pipeline updates

David Berman, M.D., Ph.D., Chief Development Officer

Looking Ahead

Stéphane Bancel, CEO

© 2026 Moderna, Inc. All rights reserved.

Visuals: Five circular line icons, each about 4.8% wide, arranged in a vertical column at x 23.2%. Row 1 (y 16.7%): grey #C0C0C0 outline circle containing a stylised wave/curve line icon with small bars. Row 2 (y 32.4%): grey #C0C0C0 outline circle containing a presentation board with a bar chart and pie chart. Row 3 (y 48.4%): red #E31837 outline circle containing blue test-tube/vial icons with red caps, representing business updates; this row is highlighted. Row 4 (y 63.8%): grey #C0C0C0 outline circle containing a figure at a microscope beside hexagon molecule shapes. Row 5 (y 79.5%): grey #C0C0C0 outline circle containing two rows of rectangles with arrows pointing right, representing looking ahead. Plus one Moderna wordmark logo in red with a row of small cyan dashes beneath it, bottom-right. None of the icons are photographic.

Slide 12

Advancing a multi-year revenue growth strategy

3Q 2026 Update |

Business updates

2026

2027

2028

Infectious disease vaccines

Geographic expansion

Oncology therapeutics

Rare disease therapeutics

PA

mRNA-4359

Intismeran

Norovirus

Flu + COVID

Flu

LATAM & APAC strategic agreements

EU market growth

mNEXSPIKE

UK, Can, Aus strategic partnerships

Executing our strategy

mFLUSIVA®: FDA approval for 50-64 years of age; accelerated approval for adults 65+; approved in Canada for adults 50+

mCOFLU®: Approved in Canada for adults 50+ (known as mCOMBRIAX® in the EU)

mNEXSPIKE®: Annual strain approvals secured in U.S., Canada, Japan, Taiwan

mRESVIA®: Continued progress in U.S. placement and ex-U.S. awards

Mexico: Signed 5-year agreement for COVID-19 vaccines with local manufacturer

Intismeran: Positive Phase 3 data in adjuvant melanoma study presented at ESMO

12

© 2026 Moderna, Inc. All rights reserved.

moderna

Visuals: One roadmap illustration (diagram) occupying the left column. It shows three house-shaped outlined columns, one each for 2026, 2027 and 2028, rising in height from left to right, with a grey (#E6E6E6) rising band behind them and a dark navy (#1F2A44) diagonal line running from the left edge at about 65% of the image height up to the right edge at about 40% of the image height. Each column contains stacked rounded rectangles with labels. 2026 column (lowest): red 'mNEXSPIKE' box above a light blue 'UK, Can, Aus strategic partnerships' box. 2027 column: navy 'Intismeran' box at top, red 'Flu' box below it, then light blue 'LATAM & APAC strategic agreements' and light blue 'EU market growth' boxes. 2028 column (tallest): light steel blue 'PA' box at top, navy 'mRNA-4359' box below it, then red 'Norovirus' and red 'Flu + COVID' boxes. A legend at top-left of the graphic lists four colour swatches: red 'Infectious disease vaccines', light blue 'Geographic expansion', navy 'Oncology therapeutics', steel blue 'Rare disease therapeutics'. No values or axis scales are printed; the chart is not quantitative. The image is not cropped and is boxed on white with no overlay. The moderna logo is a red wordmark with a row of blue dashes beneath it, and there are no other icons.

Slide 13

Infectious disease vaccines: approved products

Business updates

3Q 2026 Update |

Deliveries underway in

markets worldwide

XFG strain approved

in U.S., EU, Canada,

Japan, Taiwan for

2026/2027 season

Supplying U.S., Japan, Taiwan,

Spain with planned 2028

market expansion

XFG strain approved

in U.S., Canada,

Japan, Taiwan for

2026/2027 season

Additional filings

planned for 2H26

Approved in 44 countries

Clinical study: Safety

and immunogenicity

of revaccination

following a protein

subunit RSV vaccine1

Approved in

U.S., Canada

U.S. FDA approval for

adults 50-64 and

accelerated approval in

adults 65+

Recommended by

AAFP for adults 65+ as

an enhanced influenza

vaccine

Approved in Canada

for adults 50+

Under review in the EU,

Australia, and Taiwan

Approved in EU, Canada

Approved in Canada

for adults 50+ under

brand name mCOFLU®

Under review in

Japan, UK, Australia,

Switzerland

Awaiting further

guidance from FDA

on refiling in the U.S.

New update

1. https://www.sciencedirect.com/science/article/pii/S0264410X26008777

© 2026 Moderna, Inc. All rights reserved.

13

Visuals: Five product cards, each a white rounded rectangle with a thin light-grey outline and a coloured header tab along its top edge. Card 1 (spikevax): tab #085B81, logo spikevax with 'COVID-19 Vaccine, mRNA', subhead 'Deliveries underway in markets worldwide', one red arrow bullet. Card 2 (mNEXSPIKE): tab #00837B, logo mNEXSPIKE with 'COVID-19 Vaccine, mRNA' (teal hexagon with red wave), subhead 'Supplying U.S., Japan, Taiwan, Spain with planned 2028 market expansion', one red arrow bullet and one dot bullet. Card 3 (mRESVIA): tab #77A4D9, logo mRESVIA with '(Respiratory Syncytial Virus Vaccine)' (blue hexagon with red wave), subhead 'Approved in 44 countries', one red arrow bullet. Card 4 (mFLUSIVA): tab #B65379, logo mFLUSIVA with 'Influenza Vaccine, mRNA' (magenta ring with red wave), subhead 'Approved in U.S., Canada', three red arrow bullets and one dot bullet. Card 5 (mCOMBRIAX): tab #F37877, logo mCOMBRIAX with 'Influenza and COVID-19, mRNA Vaccine' (coral hexagon with wave), subhead 'Approved in EU, Canada', one red arrow bullet and two dot bullets. Footer: a 'New update' tag with a red arrow icon, and the Moderna wordmark in red.

Slide 14

Business updates / 3Q 2026 Update | / U.S. respiratory vaccination demand remains resilient / U.S. retail + LTC respiratory vaccines market remains stable / Season-to-date through October 30, 2026 | Retail + LTC / Flu / 27.0M / 29.1M / COVID-19 / 14.5M / 14.0M / RSV / 1.3M / 1.0M / All / respiratory / vaccines / 42.9M / 44.1M / +3% / 2025/26 season as of 10/31/25* / 2026/27 season as of 10/30/26 / Totals may differ due to rounding / *Prior-year date assumes the corresponding reporting week / Strong momentum / Robust flu and COVID-19 activity / continues into late October, / bringing total respiratory / vaccinations closer to 2025/26 / season levels / Source: IQVIA, retail + LTC shots in arms, week ending October 30, 2026. Rounded values. / © 2026 Moderna, Inc. All rights reserved. / 14 / (Moderna logo)

Visuals: Chart: grouped horizontal bar chart, titled 'U.S. retail + LTC respiratory vaccines market remains stable', season-to-date through October 30, 2026, Retail + LTC. Categories top to bottom: Flu, COVID-19, RSV, All respiratory vaccines. Two series per category: light blue bar = 2025/26 season as of 10/31/25* (#BDE5F3), dark blue bar = 2026/27 season as of 10/30/26 (#2AACE2). Printed values: Flu 27.0M (2025/26) and 29.1M (2026/27); COVID-19 14.5M and 14.0M; RSV 1.3M and 1.0M; All respiratory vaccines 42.9M and 44.1M. No axis, axis ticks or gridlines are printed; bar lengths are roughly proportional to values (about 1.1% of slide width per million). The All respiratory vaccines row is highlighted with a light grey band and shows a red callout '+3%' to its right. Horizontal dark grey rules separate Flu, COVID-19 and RSV rows; no rule under RSV. Legend below the chart: light blue square with '2025/26 season as of 10/31/25*' and dark blue square with '2026/27 season as of 10/30/26'. Logo: Moderna wordmark in red lowercase with a row of short cyan dashes beneath it.

Slide 15

Infectious disease vaccines: late-stage pipeline

Business updates

3Q 2026 Update |

Norovirus

mRNA-1403

In Phase 3

•

Phase 3 interim analysis

did not meet statistical

criteria for early success

Moderna has decided not

to enroll an additional

cohort this season

Company is engaging

Health Authorities to

determine next steps for

the program

New update

15

© 2026 Moderna, Inc. All rights reserved.

moderna

Visuals: No charts, tables or photographs. Three non-text graphic elements: (1) a card, a white rounded rectangle with a thin light-grey outline and a soft shadow, with a solid red #E31837 cap across its top edge; the card has a pale pink #FACED4 tag bar reading 'In Phase 3' and contains three bullet items. (2) Three red #E31837 right-pointing block arrow icons: two sit as bullet markers beside the second and third bullet items in the card, and one sits inside the 'New update' box at bottom-left. The first bullet item uses a plain black round bullet. (3) The Moderna logo at bottom-right: the lowercase red #E31837 wordmark 'moderna' with a small registered mark, above a row of short dashed cyan-blue (#2AACE2-like) line segments. The logo is a placed raster image, 359 by 81 pixels, not cropped.

Slide 16

3Q26 earnings call agenda / Business Review / Stéphane Bancel, CEO / Financials / Jamey Mock, CFO / Business updates / Stephen Hoge, M.D., President / Pipeline updates / David Berman, M.D., Ph.D., Chief Development Officer / Looking Ahead / Stéphane Bancel, CEO / © 2026 Moderna, Inc. All rights reserved.

Visuals: Five grey outlined line icons in circles and one red-outlined icon in a circle. Icon 1 (Business Review): a grey circle containing a grey wavy curve with small tick marks, like a smoothed line trend. Icon 2 (Financials): a grey circle containing a grey dashboard window with a small bar chart and a pie-slice clock symbol. Icon 3 (Business updates): a grey circle containing three diagonal grey test tubes or pipettes stacked in parallel. Icon 4 (Pipeline updates): a red (#E21D39) circle outline containing a sky-blue microscope with a red hexagonal molecule cluster to its right and a blue stage base. Icon 5 (Looking Ahead): a grey circle containing two rows of rounded boxes each followed by an outlined right-pointing arrow. Circles are about 4.8% of slide width and have a light grey (#C0C0C0) stroke, no fill. The Pipeline row is outlined by a red (#E21D39) rounded rectangle stroke about 0.5% of slide height thick with a transparent interior. The Moderna logo is a red (#E31837) lowercase wordmark 'moderna' with a registered mark, above a row of short sky-blue dashes.

Slide 17

Oncology therapeutics / Intismeran autogene / mRNA-4157 / In partnership with Merck / Phase 3 / Phase 2 / Phase 1 / • Adjuvant melanoma / fully enrolled / ESMO 2026: Presidential Symposium , ESMO 2026 1 / In press, New England Journal of Medicine / • Adjuvant non-small cell lung cancer (NSCLC) / fully enrolled / • Adjuvant NSCLC non-pCR post neoadjuvant / • Adjuvant NSCLC (Stage 1), intismeran / monotherapy and in combination with / KEYTRUDA QLEX / • Adjuvant muscle invasive bladder / cancer (MIBC) / fully enrolled / • Adjuvant renal cell carcinoma (RCC) / fully enrolled / • Non-muscle invasive bladder cancer / (NMIBC) / • First-line metastatic melanoma / • First-line metastatic squamous NSCLC / • Adjuvant pancreatic cancer / fully enrolled / ESMO 2026: Poster presentation 2 / • Peri-operative gastric cancer / fully enrolled / 3Q 2026 Update | Pipeline updates / New update / 1. https://irp.cdn-website.com/89dd0539/files/uploaded/Long_LBA1_ESMO+2026.pdf / 2. https://irp.cdn-website.com/89dd0539/files/uploaded/mRNA-4157-P101+Poster_ESMO+2026_Final.pdf / 17 / © 2026 Moderna, Inc. All rights reserved.

Visuals: Visual elements: three light lavender (#CDD4E9) phase heading bars, a navy (#1E2846) header strip behind the card top edge, red (#E31837) right-pointing arrow icons marking three lines (before ESMO 2026 Presidential Symposium, before Adjuvant non-small cell lung cancer (NSCLC), and before ESMO 2026 Poster presentation) and one red arrow inside the New update tag, and the Moderna logo (wordmark in red with a dashed cyan underline, 359 by 81 pixels). Bullets are black round dots. No charts, photographs or diagrams.

Slide 18

Phase 3 results demonstrate a 42% reduction in the risk of / recurrence or death

RFS Primary Analysis: ITT

100

90

80

70

60

50

40

30

20

10

0

RFS (%)

HR 0.58 (95% CI 0.45–0.75)

P < 0.001 (two sided)a

82.2% (95% CI 79.3–84.8)

70.0% (95% CI 65.0–74.5)

N Events, n (%)

Intismeran + pembrolizumab 757 136 (18.0%)

Placebo + pembrolizumab 380 111 (29.2%)

0 6 12 18 24 30 35

Months

No. at risk

757 683 646 618 136 10 0

380 341 302 282 72 3 0

aMultiplicity-adjusted significance level: two-sided 0.024692.

ITT: all randomized patients according to the arm to which they were assigned.

RFS: time from randomization to the first occurrence of any recurrence or death from any cause. Data cutoff date: June 30, 2026 (median study follow-up, 24.6 mo).

Presented by: Georgina V. Long, Melanoma Institute Australia

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.

Key takeaways

First positive Phase 3 study for / individualized neoantigen / therapy

First positive Phase 3 study / versus anti-PD1 in adjuvant / melanoma

© 2026 Moderna, Inc. All rights reserved.

18

3Q 2026 Update | Pipeline updates

Visuals: Chart: Kaplan-Meier style step chart titled RFS Primary Analysis: ITT. Y axis labelled RFS (%) ranging 0 to 100 with ticks every 10. X axis labelled Months ranging 0 to 35 with labelled ticks at 0, 6, 12, 18, 24, 30 and 35. Series 1, teal (Intismeran + pembrolizumab, N=757, events 136 (18.0%)): about 100 at 0 months, about 87 at 12 months, about 84 at 18 months, about 82.2 at 24 months as printed label 82.2% (95% CI 79.3–84.8), ending about 72 to 73 at 34 months (estimated). Series 2, blue (Placebo + pembrolizumab, N=380, events 111 (29.2%)): about 100 at 0 months, about 80 at 12 months, about 75 at 18 months, about 70.0 at 24 months as printed label 70.0% (95% CI 65.0–74.5), flattening near 69 to 70 to 34 months (estimated). Highlighted point: a dashed black vertical reference line at 24 months with the two printed 24-month labels beside it. Table inside plot (acts as legend): header row grey #C8C8C8-ish with columns blank, N, Events n (%); row 1 Intismeran + pembrolizumab 757, 136 (18.0%); row 2 Placebo + pembrolizumab 380, 111 (29.2%). Below the axis, a No. at risk table with rows: teal 757, 683, 646, 618, 136, 10, 0 at 0, 6, 12, 18, 24, 30, 35 months; blue 380, 341, 302, 282, 72, 3, 0 at the same times. Annotation text HR 0.58 (95% CI 0.45–0.75) and P < 0.001 (two sided) in navy in the plot's lower-left. The chart is a bitmap image with a thin grey drop shadow, boxed, not cropped. Right column: no images. ESMO Madrid 2026 congress logo at bottom-right of the chart panel, showing a small blue MADRID 2026 tag and the multicoloured ESMO wordmark with the word congress in small red text.

Slide 19

Phase 2 results demonstrate greater RFS benefit with longer follow-up / 3Q 2026 Update | Pipeline updates / Primary analysis 1 / 3-year analysis 2 / 5-year analysis 3 / Recurrence-Free Survival, % / Time From First Dose of Pembrolizumab, Months / + Censored / Intismeran plus pembrolizumab / Pembrolizumab / (at-risk counts as shown in visuals) / Primary analysis / 3-year follow-up / 5-year follow-up / Phase 2 / 0.56 (median F/U: 23 months 4) / 0.51 (median F/U: 34.9 months) / 0.51 (median F/U: 60.3 months) / Phase 3 / 0.58 (median follow-up: 24.6 months) / TBD / TBD / 1. https://irp.cdn-website.com/89dd0539/files/uploaded/MMA-75572-AACR-23-mRNA4157combined_version-2.pdf / 2. https://irp.cdn-website.com/89dd0539/files/uploaded/asco-2024-adjuvant-melanoma.pdf / 3. https://irp.cdn-website.com/89dd0539/files/uploaded/Intismeran+5-yr+Update+Oral+Presentation_ASCO_28May2026.pdf / 4. Median follow-up: 23 months in active arm, 24 months in control arm / 19 / © 2026 Moderna, Inc. All rights reserved. / moderna

Visuals: Three Kaplan-Meier survival plots, combined in one placed image spanning about 3% to 99% of width and 18.8% to 62.7% of height, each with its own heading above. Chart 1, Primary analysis: y-axis Recurrence-Free Survival, % from 0 to 100 in steps of 10; x-axis Time From First Dose of Pembrolizumab, Months from 0 to 48 in steps of 6. Chart 2, 3-year analysis: y-axis 0 to 100 in steps of 10; x-axis 0 to 54 in steps of 6. Chart 3, 5-year analysis: y-axis 0 to 100 in steps of 10; x-axis 0 to 66 in steps of 6. Each chart has two step curves with censoring tick marks: red (Intismeran plus pembrolizumab, 107 patients at start) and blue (Pembrolizumab, 50 patients at start). Legend at top-right of each plot reads + Censored. Primary chart: red about 80% at 24 months, about 77% at 30 months, about 72% at 37 months, about 58% at 47 months; blue about 78% at 18 months, about 64% at 24 months, about 56% from 33 months to 48 months. 3-year chart: red about 80% at 24 months, about 75% at 35 months, about 70% at 48 months; blue about 70% at 16 months, about 56% at 29 months, about 27% at 42 months. 5-year chart: red about 81% at 18 months, about 77% at 30 months, about 73% at 48 months, about 69% at 60 months; blue about 71% at 15 months, about 56% at 25 months, about 49% at 44 months to 60 months. At-risk tables beneath each plot, red row (Intismeran plus pembrolizumab) and blue row (Pembrolizumab) in matching colours. Primary: red 107, 88, 82, 49, 24, 8, 3, 0, 0; blue 50, 41, 37, 28, 11, 1, 1, 0, 0 at 0, 6, 12, 18, 24, 30, 36, 42, 48 months. 3-year: red 107, 87, 83, 77, 52, 29, 12, 6, 1, 0; blue 50, 41, 37, 29, 27, 10, 5, 2, 0, 0 at 0 to 54 months. 5-year: red 107, 89, 84, 78, 74, 70, 57, 55, 39, 20, 3, 0; blue 50, 41, 37, 29, 27, 22, 19, 17, 12, 7, 3, 0 at 0 to 66 months. Table with three value columns (Primary analysis, 3-year follow-up, 5-year follow-up) and two rows (Phase 2, Phase 3), light blue header band; Phase 2 values 0.56 (median F/U: 23 months 4), 0.51 (median F/U: 34.9 months), 0.51 (median F/U: 60.3 months); Phase 3 values 0.58 (median follow-up: 24.6 months), TBD, TBD. Moderna wordmark logo in red bottom-right with a dashed light-blue underline of alternating blue and light-blue dashes.

Slide 20

Pipeline updates

3Q 2026 Update |

mITT analysis shows a greater RFS benefit among patients who

received intismeran as planned

mITT population excludes

participants who did not receive

at least one dose of intismeran

or placebo as planned

RFS Sensitivity Analysis: mITT

RFS (%)

100

90

80

70

60

50

40

30

20

10

0

HR 0.51 (95% CI 0.39–0.67)

84.2% (95% CI 81.3–86.7)

70.4% (95% CI 65.3–74.9)

N

Events,a n (%)

Intismeran + pembrolizumab 726 116a (16.0%)

Placebo + pembrolizumab 365 106b (29.0%)

0 6 12 18 24 30 35

Months

No. at risk

726 674 638 611 133 9 0

365 333 294 275 71 2 0

a31 patients in the intismeran + pembrolizumab arm were excluded from the mITT population due to AEs (n=13), recurrence (n=10), or other reason (n=8). RFS events occurred in 20 (64.5%) of the 31 patients who did not receive intismeran as planned. b15 patients in the placebo + pembrolizumab arm were excluded from the mITT population due to AEs (n=5), recurrence (n=4), or other reason (n=6). RFS events occurred in and 5 (33.3%) of 15 patients who did not receive placebo as planned. mITT: all randomized patients who received intismeran or placebo as assigned. RFS: time from randomization to the first occurrence of any recurrence or death from any cause. Data cutoff date: June 30, 2026 (median study follow-up, 24.6 mo).

Presented by: Georgina V. Long, Melanoma Institute Australia

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.

a. Randomization stratification factors applied to all stratified analyses.

© 2026 Moderna, Inc. All rights reserved.

20

Visuals: One Kaplan-Meier survival chart, a raster image (the file contains a 1758 by 989 pixel version and an overlapping 891 by 506 pixel copy in the same box), placed at x 4.9 to 71.7 percent and y 20.0 to 87.4 percent, boxed with a thin light grey drop shadow, full-width of its box with no crop. Chart title printed inside: 'RFS Sensitivity Analysis: mITT' in bold dark navy #0B2A4A at top left. Chart type: line (Kaplan-Meier step curves) with censoring tick marks. Y axis: 'RFS (%)', range 0 to 100 with ticks every 10, labelled 0, 10, 20 ... 100. X axis: 'Months', range 0 to 35 with labelled ticks at 0, 6, 12, 18, 24, 30, 35. Series 1: Intismeran + pembrolizumab, teal-green line #00897B, labelled 84.2% (95% CI 81.3-86.7) at 24 months; plateaus near 85 to 90 percent and steps down to about 82 percent around 28 months and about 74 percent near 33 months. Series 2: Placebo + pembrolizumab, blue line #1F4FA0, labelled 70.4% (95% CI 65.3-74.9) at the end of follow-up; falls to about 84 percent near 8 months, about 80 percent near 12 months, about 75 percent near 18 months, and about 70 percent from 27 months onward. Highlighted point: a vertical black dashed reference line at 24 months. Annotation: 'HR 0.51 (95% CI 0.39-0.67)' in navy at upper left of the plot area. Embedded table at lower left of plot area with a light grey header row and two data rows: columns 'Events,a n (%)' with header cells 'N' and 'Events,a n (%)'; row 1 'Intismeran + pembrolizumab' N 726, events 116a (16.0%); row 2 'Placebo + pembrolizumab' N 365, events 106b (29.0%). Below the x axis a 'No. at risk' table: row 1 teal values 726, 674, 638, 611, 133, 9, 0 at months 0, 6, 12, 18, 24, 30, 35; row 2 blue values 365, 333, 294, 275, 71, 2, 0. Legend: none; series are identified by the coloured labels in the table. Footnote paragraph in small grey text at the bottom of the image, with a bold 'Presented by' line and a copyright line. A small ESMO and Madrid 2026 congress logo sits at the bottom right corner of the image box.

Slide 21

Safety findings were consistent with the known profiles of / the individual therapies / 3Q 2026 Update | / Pipeline updates / AEs of Interest for Pembrolizumab, Incidence ≥1% / Intismeran did not potentiate pembrolizumab-associated AEs / Intismeran + Pembrolizumab (N = 755) / Placebo + Pembrolizumab (N = 380) / Any 36.0 34.7 / Hypothyroidism 15.9 16.1 / Hyperthyroidism 9.9 8.2 / Infusion reactions 3.3 1.1 / Colitis 2.6 3.2 / Gastritis 2.1 0.8 / Adrenal insufficiency 1.7 4.2 / Pneumonitis 1.7 2.1 / Hepatitis 1.6 2.1 / Severe skin reactions 1.6 0.3 / Hypophysitis 1.5 1.1 / Type 1 diabetes mellitus 1.5 1.1 / Myositis 1.2 1.6 / Thyroiditis 1.2 0.8 / 100 90 80 70 60 50 40 30 20 10 0 10 20 30 40 50 60 70 80 90 100 / Incidence, % / Grade 1–2 / Grade 3–5 / Grade 1–2 / Grade 3–5 / As-treated population: all randomized patients who received at ≥1 dose of study treatment. Data cutoff date: June 30, 2026 (median study follow-up, 24.6 mo). / Presented by: Georgina V. Long, Melanoma Institute Australia / Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. / AEs of interest for intismeran were / consistent with expected profile / • The most common AEs in the / intismeran + KEYTRUDA arm were / pyrexia (52.2%), injection site pain / (51.0%), and fatigue (38.5%) / • AEs were generally low-grade, / transient, and managed with standard / supportive care / 21 / © 2026 Moderna, Inc. All rights reserved.

Visuals: One chart (image): a horizontal butterfly (back-to-back bar) chart titled AEs of Interest for Pembrolizumab, Incidence ≥1%, with subtitle Intismeran did not potentiate pembrolizumab-associated AEs. Left side is Intismeran + Pembrolizumab (N = 755), right side is Placebo + Pembrolizumab (N = 380). Category axis lists 14 AEs top to bottom: Any, Hypothyroidism, Hyperthyroidism, Infusion reactions, Colitis, Gastritis, Adrenal insufficiency, Pneumonitis, Hepatitis, Severe skin reactions, Hypophysitis, Type 1 diabetes mellitus, Myositis, Thyroiditis. Horizontal axis is labelled Incidence, %, ranging from 100 on the left to 0 at centre to 100 on the right, with ticks every 10. Each bar is stacked by grade. Printed values, intismeran (left) then placebo (right): Any 36.0 / 34.7; Hypothyroidism 15.9 / 16.1; Hyperthyroidism 9.9 / 8.2; Infusion reactions 3.3 / 1.1; Colitis 2.6 / 3.2; Gastritis 2.1 / 0.8; Adrenal insufficiency 1.7 / 4.2; Pneumonitis 1.7 / 2.1; Hepatitis 1.6 / 2.1; Severe skin reactions 1.6 / 0.3; Hypophysitis 1.5 / 1.1; Type 1 diabetes mellitus 1.5 / 1.1; Myositis 1.2 / 1.6; Thyroiditis 1.2 / 0.8. Legend below the axis: Grade 1–2 light green swatch, Grade 3–5 teal swatch, Grade 1–2 light blue swatch, Grade 3–5 dark blue swatch. No highlighted points. The chart image has a faint drop shadow and a small ESMO congress logo at its bottom-right corner. The moderna wordmark in red with a row of dashed light blue and cyan underline dashes is a logo at bottom-right.

Slide 22

Oncology therapeutics

3Q 2026 Update | Pipeline updates

22

Cancer antigen

therapies

mRNA-4359

Phase 2

Phase 2 in first-line metastatic melanoma, second-line+ metastatic melanoma, and first-line metastatic NSCLC

mRNA-4194

Phase 1/2

Phase 1/2 study dosing in Lynch Syndrome

mRNA-4106 / mRNA-4200

Phase 1

Phase 1 study dosing in advanced solid tumors:

mRNA-4106

mRNA-4200

T-cell

engager

mRNA-2808

Phase 1/2

Phase 1/2 study in

multiple myeloma dosing

Abstract accepted for

oral presentation at

ASH 2026

Cell therapy-

enhancer +

anzu-cel

mRNA-4203 + IMA203

Phase 1

Cell therapy-enhancer + anzu-cel (anzutresgene autoleucel, IMA203) Phase 1 study dosing

In collaboration with Immatics

New update

moderna

© 2026 Moderna, Inc. All rights reserved.

Visuals: No photographs or charts. Visual elements: (1) three card containers, each with a dark navy top bar and white rounded body with a thin light-grey outline; (2) three light lavender-grey phase tags (Phase 2, Phase 1/2, Phase 1 in the left card; Phase 1/2 in the middle card; Phase 1 in the right card) drawn as flat rectangles with no rounding; (3) small bullet glyphs (round dots) before body lines; (4) two solid red right-pointing arrow icons: one beside 'Abstract accepted for' in the middle card, one inside the 'New update' tag; (5) the Moderna logo at bottom-right: lowercase red wordmark 'moderna' (#E31837) above a row of short dashes in light cyan (#2AACE2 to pale blue) that alternate with gaps. No other icons or images.

Slide 23

Rare disease therapeutics pipeline / 3Q 2026 Update | Pipeline updates / PA / mRNA-3927 / Phase 2 / • In a registrational study; target enrollment reached / MMA / mRNA-3705 / Phase 2 / • Company deferred decision on pivotal trial until PA readout / 23 / © 2026 Moderna, Inc. All rights reserved.

Visuals: Two rounded-corner portrait cards, each with a blue top tab. Card 1 (left): tab #6393C0, white body with a faint light-grey outline, title PA, subtitle mRNA-3927, a light blue-grey phase label bar reading Phase 2, and one bullet. Card 2 (right): identical structure with title MMA, subtitle mRNA-3705, Phase 2 label, and one bullet. No chart, photograph or icon. Bottom-right logo: the Moderna wordmark in red #E31837 lowercase, with a row of short dashes beneath it in a light-to-dark cyan-blue gradient.

Slide 24

3Q26 earnings call agenda / Business Review / Stéphane Bancel, CEO / Financials / Jamey Mock, CFO / Business updates / Stephen Hoge, M.D., President / Pipeline updates / David Berman, M.D., Ph.D., Chief Development Officer / Looking Ahead / Stéphane Bancel, CEO / © 2026 Moderna, Inc. All rights reserved.

Visuals: Five circular line icons in light grey (#C0C0C0) outline strokes, each about 4.8% wide, placed in a column at x 23.2%: the first at y 16.7% shows a wavy line chart (business review); the second at y 32.4% shows a presentation board with bar chart and pie chart (financials); the third at y 48.4% shows three rulers or measuring tools arranged diagonally (business updates); the fourth at y 63.8% shows a scientist at a microscope beside a hexagon molecule cluster (pipeline updates). The fifth icon at y 79.5% is a red (#E21D39) circle outline containing two rows of blue (#2AACE2) rounded capsule shapes each followed by a red outlined arrow pointing right (looking ahead). Below-right: moderna wordmark logo in red (#E21D39) lowercase letters with a row of short dashed cyan (#2AACE2) lines underneath, placed at x 86.6% y 92.2% w 12.2% h 4.9%. No photographs or charts.

Slide 25

2026 value drivers / Looking Ahead / 3Q 2026 Update | / Commercial + / financial performance / Potential / approvals / Potential clinical / milestones / Updated expected 2026 / revenue growth to 15-25%, / exceeding previous expectation of up to 10% / 2026 adjusted cash / cost¹ target: $3.8B / improvement by $0.2B from / previous framework / 2026 cash and investments / outlook² raised to $8.1-8.3B / increase driven by improved operational / execution and convertible note proceeds / • mNEXSPIKE in EU, / Japan, Switzerland, / Taiwan / mCOMBRIAX/mCOFLU in / EU, Canada, Japan / Flu (mRNA-1010) in the / U.S., Canada, EU / Intismeran / Five-year Phase 2 adjuvant melanoma data / Positive Phase 3 adjuvant melanoma data presented at / Presidential Symposium ESMO 2026 / • Phase 2 adjuvant renal cell carcinoma data; event-driven / Phase 1 adjuvant pancreatic poster presentation at / ESMO 2026 / • BLA submission / mRNA-2808 abstract accepted for oral presentation at / ASH on Dec 12th / • PA registrational study data / New update / 1. Excluding $0.9B for litigation settlement charge. Cash costs = GAAP expenses − stock-based compensation − depreciation and amortization / 2. Excludes any further drawdowns from the Company’s remaining $0.9B available under its credit facility / © 2026 Moderna, Inc. All rights reserved. / 25 / moderna

Visuals: Three line icons, all with a red (#E21D39) circular ring. Icon 1 (card 1, centred near x 13.6 to 20.4, y 15.8 to 27.9): a blue-outlined dashboard window with red and blue dashed text lines, a red and blue bar chart and a blue pie chart. Icon 2 (card 2, near x 38.9 to 47.3, y 14.4 to 29.4): blue concentric target rings with a red dart arrow stuck in the centre and a blue circle containing a red check mark. Icon 3 (card 3, near x 72.1 to 80.5, y 14.4 to 29.3): a blue clipboard with a red medical cross at top, red check-mark list lines and a blue magnifying glass with red handle overlapping the lower right. Red check-mark icons (red filled circles with white tick) precede each country name in the Potential approvals column (mNEXSPIKE: EU, Japan, Switzerland, Taiwan; mCOMBRIAX/mCOFLU: EU, Canada, Japan; Flu: U.S., Canada, EU) and each Intismeran sub-item in the Potential clinical milestones column (Five-year Phase 2 adjuvant melanoma data; Positive Phase 3 adjuvant melanoma data presented at Presidential Symposium ESMO 2026; Phase 1 adjuvant pancreatic poster presentation at ESMO 2026). Solid red right-pointing arrows mark the bullet lines Updated expected 2026 revenue growth, 2026 adjusted cash cost target, 2026 cash and investments outlook, the mNEXSPIKE and mCOMBRIAX/mCOFLU and Flu approvals, Intismeran, and mRNA-2808. Black filled dots mark Phase 2 adjuvant renal cell carcinoma data, BLA submission, and PA registrational study data. A small red right arrow sits inside the New update tag. The moderna logo at bottom right (about x 86.6, y 92.2, 12.2 by 4.9) is a red lowercase wordmark with a row of short cyan dashes beneath it. No photographs.

Slide 26

Upcoming events / Moderna Analyst Day / November 12, 2026 / In-person at Moderna Marlborough Facility (by RSVP) / Webcast / Looking Ahead / 3Q 2026 Update | / 26 / © 2026 Moderna, Inc. All rights reserved.

Visuals: One white line icon of a calendar with a check mark: a rounded rectangle calendar body with two binder rings at the top, a horizontal header bar, a 3x2 grid of rounded square day cells, and a large circle with a white checkmark overlapping the bottom-right corner of the calendar body. The icon is drawn in solid white on the #2AACE2 blue panel, centred at about x 6.7% to 23.5%, y 35.0% to 77.2%. Two small red line icons inside the card: a map pin (location marker) beside the in-person line, and a laptop-style screen with a globe showing a webcast beside the Webcast line. A thin red horizontal rule under the event title. The moderna wordmark in red with a row of short cyan dashes beneath it, bottom-right.

Slide 27

Our mission / Deliver the greatest possible impact / to people through mRNA medicines / 27 / © 2026 Moderna, Inc. All rights reserved.

Visuals: Two non-text elements. (1) A Moderna wordmark logo at bottom right, lowercase 'moderna' in red #E31B3B with a registered mark, above a row of short dashed underline segments in cyan #2AACE2 that step lightly across its width. (2) A full-slide blue vertical bar at the left edge in #2AACE2, a flat solid shape with no border or shadow. No photographs, charts, or diagrams are present.

Slide 28

Q&A

moderna

© 2026 Moderna, Inc. All rights reserved.

Visuals: One logo: the Moderna wordmark, set in lowercase red letters with a row of short, evenly spaced cyan dashes running beneath it, placed at the bottom-right corner (about 86.6% from left, 92.2% from top, 12.2% wide by 4.9% high; source image 359 by 81 pixels). One flat decorative shape: a solid vertical blue rectangle (#2AACE2) covering the left 19.4% of the slide, full height, with no border or gradient. No photographs, charts, tables, or diagrams.

Slide 29

Appendix / Moderna’s Pipeline / © 2026 Moderna, Inc. All rights reserved.

Visuals: Logo: Moderna wordmark in lowercase red (#E31837) letters with a row of short light-blue to cyan (#2AACE2) dashes beneath it, at the bottom-right corner. No photographs, charts, or diagrams.

Slide 30

Moderna’s pipeline: Infectious diseases

Infectious disease vaccines

Ph 1

Ph 2

Ph 3

Commercial

Respiratory viruses

COVID-19 vaccine

Spikevax®

COVID-19 vaccine

mNEXSPIKE®

RSV vaccine

mRESVIA®

Flu + COVID vaccine

mCOMBRIAX®

Flu vaccine

mFLUSIVA®

Pandemic Flu vaccine (in collaboration with CEPI*)

mRNA-1018

RSV + hMPV vaccine

mRNA-1365

RSV vaccine for adolescents + pediatrics

mRNA-1345

Enteric viruses

Norovirus vaccines

mRNA-1403

mRNA-1405

Latent viruses

CMV vaccine for transplant recipients

mRNA-1647

EBV vaccine to prevent infectious mononucleosis

mRNA-1189

EBV vaccine in multiple sclerosis

mRNA-1195

HIV vaccine (in collaboration with IAVI)

mRNA-1645

Bacterial

Lyme disease vaccines

mRNA-1975

mRNA-1982

Public health

Bundibugyo ebolavirus vaccine

mRNA-1469

Nipah vaccine

mRNA-1215

Mpox vaccine

mRNA-1769

© 2026 Moderna, Inc. All rights reserved.

30

Visuals: One table image (2005 by 1225 pixels) with a column header band and horizontal progress bars. Columns: a section label column in red (Respiratory viruses, Enteric viruses, Latent viruses, Bacterial, Public health), a bold program-name column, a bold-free code column (Spikevax®, mNEXSPIKE®, mRESVIA®, mCOMBRIAX®, mFLUSIVA®, mRNA codes), and a progress-bar column with four phase headers Ph 1, Ph 2, Ph 3 and Commercial. Each bar is a blue (#29ABE2) rounded fill inside a light grey (#D9D9D9) rounded track with a white inner edge. Rows and bar lengths: COVID-19 vaccine Spikevax® full to Commercial; COVID-19 vaccine mNEXSPIKE® full to Commercial; RSV vaccine mRESVIA® full to Commercial; Flu + COVID vaccine mCOMBRIAX® full to Commercial; Flu vaccine mFLUSIVA® full to Commercial; Pandemic Flu vaccine (in collaboration with CEPI*) mRNA-1018 about 75% of track, about Ph 3; RSV + hMPV vaccine mRNA-1365 about 20%, about Ph 1; RSV vaccine for adolescents + pediatrics mRNA-1345 about 50%, about Ph 2; Norovirus vaccines mRNA-1403 about 75%; Norovirus vaccines mRNA-1405 about 50%; CMV vaccine for transplant recipients mRNA-1647 about 50%; EBV vaccine to prevent infectious mononucleosis mRNA-1189 about 50%; EBV vaccine in multiple sclerosis mRNA-1195 about 50%; HIV vaccine (in collaboration with IAVI) mRNA-1645 about 20%; Lyme disease vaccines mRNA-1975 about 50%; Lyme disease vaccines mRNA-1982 about 50%; Bundibugyo ebolavirus vaccine mRNA-1469 about 20%; Nipah vaccine mRNA-1215 about 20%; Mpox vaccine mRNA-1769 about 50%. Bar lengths are estimates, no values printed. No legend and no highlighted points. Small icon at top-left of the header band: a red-outlined circle containing two blue-and-white capsule or pill shapes. Footnote-style text (CEPI*) is embedded in the Pandemic Flu row.

Slides 31 to 32 continue in the full text file.

Download this deck

The hosted PDF of every library deck is free for readers of the SlideDeck Co newsletter. Join with your email and the viewer and download appear here.

Preparing a results presentation or business update of your own? The SlideDeck Co Standard Deck is a slide library for business reviews, updates and plans.

More Reporting decks

Deck reviews in your inbox.

See what works in real company decks, what we’d change, and get the latest SDC releases.

Expanded slide preview